Key result
Endothelial dysfunction plays a key role in the pathogenesis of heart failure, which affects 1-2% of the worldwide population, and represents a potential target for new therapeutic development.
Why the study?
Heart failure causes high mortality and hospitalization rates, but the exact underlying pathophysiology of its genesis and progression remains poorly understood.
This review highlights the pathophysiological role of endothelial dysfunction in heart failure and emphasizes flow-mediated dilation as a key assessment tool and potential therapeutic target.
Endothelial dysfunction review in heart failure leaves open targeted therapies; prospective trials needed before clinical adoption.
Heart failure affects 1-2% of the population worldwide, and it is characterized by episodes of decompensation often requiring hospitalization. Although targeted treatment has reduced the prevalence of rehospitalizations to 30-50%, mortality rates remain high. A complex blend of structural and functional alterations accounts for the genesis and progression of heart failure, but the exact underlying pathophysiology remains poorly understood. The aim of this review is to summarize endothelial dysfunction and its role in the pathogenesis and progression of heart failure. Moreover, it sums up all the appropriate methods of assessing endothelial dysfunction emphasizing on flow-mediated dilation and introduces endothelium as a potential target for new therapeutic development and research in the wide spectrum of the syndrome called heart failure.
No takes yet. Share an insight, caveat, or question.
Giannitsi et al. (2019) conducted a review in Heart failure. Endothelial dysfunction was evaluated. Endothelial dysfunction plays a key role in the pathogenesis of heart failure, which affects 1-2% of the worldwide population, and represents a potential target for new therapeutic development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: